QSI Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

Revenue: $552,000 for Q3 2025, impacted by capital sales headwinds.
Gross Profit: $194,000 with a gross margin of 35%.
Year-to-Date Revenue: $2.0 million with a gross profit of $1.0 million and a gross margin of 52%.
Operating Expenses: GAAP total operating expenses were $40 million, up from $28.5 million in Q3 2024. Adjusted operating expenses were $21.4 million, down from $26.0 million in the same period last year.
Cash Position: As of September 30, 2025, QSI had $230.5 million in cash and marketable securities.
Guidance: Adjusted operating expenses expected to be $96 million or less for 2025, with total cash use projected at $103 million, including a $10.2 million lease termination payment.

2. Strategic Updates and Business Highlights:

Commercial Adoption: 12 new customers implemented the platform under a new instrument acquisition model, primarily in academic labs, which have been difficult to access due to NIH funding challenges.
Scientific Affairs: Five manuscripts submitted for publication, with two already published, indicating progress in building a publication pipeline.
Innovation Roadmap: Successful sequencing runs completed on multiple prototype Proteus systems, marking a significant milestone. The commercial launch of the version 4 sequencing kit occurred in early September.
Partnerships: Ongoing evaluation of partnerships to accelerate development activities and broaden market participation.

3. Forward Guidance and Outlook:

Market Expectations: Anticipated modest improvement in Q4 2025, but not a significant upswing compared to historical trends due to ongoing market challenges.
Investor Day: Upcoming updates on the Proteus program and recognizer development program are expected on November 19, 2025, including early sequencing data and future milestones.

4. Bad News, Challenges, or Points of Concern:

Capital Sales Headwinds: Continued impact from capital market uncertainties and NIH funding challenges affecting revenue.
Operating Expenses: Significant increase in operating expenses, including a $13.6 million adjustment related to a lease termination, although this is expected to save over $24 million in future operating costs.
Market Conditions: The academic sector remains slow due to capital constraints, and the overall funding environment is uncertain due to the government shutdown affecting NIH budget approvals.

5. Notable Q&A Insights:

Investor Day Expectations: Management will provide updates on the Proteus system, including data generation timelines and potential applications across various markets.
Placement Program Success: More than half of the new placements were in academic labs, indicating a strategic focus on this segment to drive future growth and publication output.
Market Dynamics: The sales cycle for biotech and pharma remains lengthy (9-12 months), and while there are pressures in academia, consumable budgets are still being utilized by new customers.
NIH Funding Outlook: Uncertainty persists regarding NIH funding due to the government shutdown, with expectations for a flat or marginally reduced budget compared to the previous year.

This summary captures the essential elements of the earnings call, providing a clear overview of QSI's financial performance, strategic initiatives, and the challenges faced in the current market environment.

QSI — Quantum-Si incorporated